207 related articles for article (PubMed ID: 34794098)
21. Potency and Selectivity Optimization of Tryptophanol-Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer.
Barcherini V; Almeida J; Lopes EA; Wang M; Magalhães E Silva D; Mori M; Wang S; Saraiva L; Santos MMM
ChemMedChem; 2021 Jan; 16(1):250-258. PubMed ID: 32737944
[TBL] [Abstract][Full Text] [Related]
22. Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors.
Gollner A; Weinstabl H; Fuchs JE; Rudolph D; Garavel G; Hofbauer KS; Karolyi-Oezguer J; Gmaschitz G; Hela W; Kerres N; Grondal E; Werni P; Ramharter J; Broeker J; McConnell DB
ChemMedChem; 2019 Jan; 14(1):88-93. PubMed ID: 30458062
[TBL] [Abstract][Full Text] [Related]
23. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
24. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
25. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
Aguilar A; Sun W; Liu L; Lu J; McEachern D; Bernard D; Deschamps JR; Wang S
J Med Chem; 2014 Dec; 57(24):10486-98. PubMed ID: 25496041
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2-p53 interaction.
Barakat A; Islam MS; Ghawas HM; Al-Majid AM; El-Senduny FF; Badria FA; Elshaier YAMM; Ghabbour HA
Bioorg Chem; 2019 May; 86():598-608. PubMed ID: 30802707
[TBL] [Abstract][Full Text] [Related]
27. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
28. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
29. Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
Grigoreva TA; Novikova DS; Petukhov AV; Gureev MA; Garabadzhiu AV; Melino G; Barlev NA; Tribulovich VG
Bioorg Med Chem Lett; 2017 Dec; 27(23):5197-5202. PubMed ID: 29089230
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
31. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
[TBL] [Abstract][Full Text] [Related]
32. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
33. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity.
Al-Rashood ST; Hamed AR; Hassan GS; Alkahtani HM; Almehizia AA; Alharbi A; Al-Sanea MM; Eldehna WM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):831-839. PubMed ID: 32208781
[TBL] [Abstract][Full Text] [Related]
34. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.
Zhang L; Ren W; Wang X; Zhang J; Liu J; Zhao L; Zhang X
Eur J Med Chem; 2017 Jan; 126():1071-1082. PubMed ID: 28027532
[TBL] [Abstract][Full Text] [Related]
36. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells.
Putri HE; Nutho B; Rungrotmongkol T; Sritularak B; Vinayanuwattikun C; Chanvorachote P
Phytomedicine; 2021 May; 85():153534. PubMed ID: 33773191
[TBL] [Abstract][Full Text] [Related]
37. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
38. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.
Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C
J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
